Patent
In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71 in another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
1. An isolated non-lipidated and non-pyruvylated polypeptide comprising an amino acid sequence set forth as SEQ ID NO: 68, wherein an N-terminal cysteine at position 1 is deleted, as compared to SEQ ID NO: 15.
2. An isolated non-lipidated and non-pyruvylated polypeptide comprising an amino acid sequence set forth as SEQ ID NO: 68, wherein an N-terminal cysteine at position 1 is substituted, as compared to SEQ ID NO: 15.
3. The polypeptide according to claim 1 , wherein the polypeptide is immunogenic.
4. The polypeptide according to claim 1 , wherein the polypeptide does not exhibit a mass shift of about +70 Da compared to the corresponding non-lipidated polypeptide as measured by mass spectrometry.
5. The isolated polypeptide according to claim 1 , wherein the amino acid sequence consists of the sequence set forth in SEQ ID NO: 68.
6. The isolated polypeptide according to claim 5 , wherein the polypeptide is encoded by the nucleic acid sequence SEQ ID NO: 69.
7. The isolated polypeptide according to claim 1 wherein the amino acid sequence consists of the sequence set forth as SEQ ID NO: 64.
8. The isolated polypeptide according to claim 7 , wherein the polypeptide is encoded by the nucleic acid sequence SEQ ID NO: 63.
9. An immunogenic composition comprising the polypeptide as in any of claims 1 , 3 , 4 , 5 , 6 , 7 , and 6 .
10. The composition according to claim 9 , further comprising an adjuvant.